We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Idebenone
A synthetic short-chain analog of coenzyme Q10 designed to support mitochondrial electron transport and act as an antioxidant. Important context: it has almost entirely been studied as a prescription DRUG (approved for Leber hereditary optic neuropathy in the EU as Raxone), not as an OTC supplement — and even its drug trials are mixed, with several outright negative neurological endpoints.
What the evidence says
Idebenone doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1992–2026.
Based on 57 studies · 6 meta-analyses · 32 RCTs
Confidence
High confidenceBy outcome
Scored low/Emerging because idebenone is studied as a prescription drug with mixed-to-null results: the pivotal LHON trial missed its primary endpoint, Friedreich ataxia trials were negative, and OTC supplement efficacy is unestablished.
31 randomised trials
94% were about Idebenone in an audit of 31 of them
Every randomised or controlled trial of Idebenone indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
3 trials ongoing or recruiting · 22 completed on ClinicalTrials.gov
12 of the completed trials have posted results
Registered trials show research momentum for Idebenone, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Oct 2026
Idebenone is a synthetic, shorter-tailed analog of coenzyme Q10 that can shuttle electrons in the mitochondrial respiratory chain and scavenge free radicals, with the theoretical advantage of better water solubility and brain penetration than CoQ10.
Crucially, idebenone has been developed and studied primarily as a pharmaceutical, not a dietary supplement: it is approved in the EU (as Raxone) for Leber hereditary optic neuropathy (LHON), a mitochondrial cause of vision loss. The evidence base is genuinely mixed.
In LHON, the pivotal RHODOS randomized trial missed its primary visual-acuity endpoint, with benefit appearing only in a post-hoc subgroup of patients with discordant baseline vision.
In Friedreich ataxia, multiple randomized placebo-controlled trials found NO significant benefit on neurological function or cardiomyopathy. Older Alzheimer's-disease studies suggested modest cognitive benefit, but a later large US trial was negative.
So while the mitochondrial rationale is real, idebenone should be understood as a drug with mixed-to-null results on most endpoints — not a well-validated cognitive or vision supplement.
As a CoQ10 analog, idebenone can transfer electrons in the respiratory chain, theoretically supporting ATP production in dysfunctional mitochondria.
Scavenges free radicals and may reduce lipid peroxidation, with relatively good water solubility and CNS penetration versus CoQ10.
How Idebenone works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Use only under specialist/neuro-ophthalmology care — this is a prescription indication.
Not adequately studied — avoid.
Idebenone is metabolized via CYP3A4; strong inhibitors/inducers could alter its levels. Discuss with a clinician.
Tip: Take with food
Tip: Idebenone can colour urine reddish or orange, but colour alone cannot exclude blood. If blood is possible or you are unsure, get prompt medical advice today, even if it happens once.
Tip: Reduce dose
Idebenone has an evidence score of 3/10 — emerging evidence based on 58 indexed studies. A synthetic short-chain analog of coenzyme Q10 designed to support mitochondrial electron transport and act as an antioxidant. Important context: it has almost entirely been studied as a prescription DRUG (approved for Leber hereditary optic neuropathy in the EU as Raxone), not as an OTC supplement — and even its drug trials are mixed, with several outright negative neurological endpoints. Representative study: PMID 21788663.
Dosing for Idebenone: The cited drug trial (Leber hereditary optic neuropathy) used 900 mg/day. There is no validated OTC supplement dose. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Idebenone is with meals. Take it with food. Absorption improves with food (fat); pharmaceutical regimens divide the dose across meals.
Idebenone has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. Reported side effects include mild GI upset (nausea, diarrhea), reddish/orange discoloration of urine, headache. How often they occur is not established for all of them. Use caution if any of these apply to you: Pregnancy/breastfeeding (not adequately studied); Known hypersensitivity to idebenone.
Smoking status: not checked. AREDS2 Formula: what these mean for you changes depending on whether you smoke or used to, and you have not told us. That check was skipped.
AREDS2 Formula
Too few graded studiesThe one supplement formula with randomised-trial evidence for slowing age-related macular degeneration — but only in people who already have intermediate AMD or advanced AMD in one eye. It does not prevent AMD, and it does not restore vision that has been lost. AREDS2's own contribution was to swap beta-carotene out, because beta-carotene raises lung cancer risk in smokers and former smokers.
Lutein + Zeaxanthin
Likely helpsCarotenoid pigments that accumulate in the eye, providing protection against blue light and age-related vision decline.
Huperzine A
Too few graded studiesAcetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
Meso-Zeaxanthin
Too few graded studiesConcentrates in the fovea, where it is studied for macular pigment density and blue-light filtering — must be supplemented or converted from lutein.
Explore: Best supplements for Focus, Memory & MoodBest supplements for Body Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 57 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research